Skip to main content
SpringerLink
Log in
Book cover

Universitätskolloquien zur Schizophrenie pp 21–46Cite as

Aktuelle Schwerpunkte der Schizophrenieforschung

  • Chapter

  • 68 Accesses

Zusammenfassung

Die Verlaufsforschung hat in der Psychiatrie u. a. die folgenden Zielsetzungen: Validierung von Krankheitskonzepten, Beschreibung des Krankheitsverlaufs unter gegebenen Behandlungsbedingungen, Subdifferenzierung von Patientengruppen, Suche nach Verlaufsprädiktoren. An der psychiatrischen Klinik der Universität München bestehen besonders günstige Rahmenbedingungen für Verlaufsuntersuchungen, da routinemäßig ein umfassendes Basis- und Befunddokumentationssystem angewandt wird. Im Rahmen dieses Dokumentationssystems werden u.a. umfangreiche Daten zum psychopathologischen Aufnahme- und Entlassungsbefund mit dem AMDP (Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie)-System erhoben. Die erhobenen Daten dienen einerseits zur Qualitätskontrolle, können aber natürlich auch wissenschaftlichen Zwecken zugeführt werden.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ackenheil M (1980) Neuroleptics. Biochemical effects (in man). In: Hoffmeister F, Stille G (Hrsg) Handbook of experimental pharmacology, vol 55/1. Springer, Berlin, Heidelberg, New York, pp 213–223

    Google Scholar 

  2. Ackenheil M (1993) Clinical biochemical investigations with classical and non-classical neuroleptics. In: New generation of antipsychotic drugs: novel mechnisms of action (4). Proc of the Workshop of the International Academy for Biochemical and Drug Research, March 16–18, 1992, in Monte Carlo, Monaco. Karger, Basel, New York, pp 91–96

    Google Scholar 

  3. Ackenheil M, Müller N (1991) Psycho-Neuro-Endokrino-Immunologie bei schizophrenen Patienten. In: Beckmann H, Osterheider M (Hrsg) Neurotransmitter und psychische Erkrankungen (Tropon-Symposium VI). Springer, Berlin, Heidelberg, S 159–168

    Google Scholar 

  4. Ackenheil M, Bartl S, Fischer B, Müller F, Wörner I, Matussek N (1980) Hormonelle Untersuchungen nach langjähriger Neuroleptikabehandlung. Arzneim Forschung (Drug Res) 30: 1205–1206

    Google Scholar 

  5. Andreasen NC, Cizadlo T, Harris G, Swayze VW, O’Leary DS, Cohen G, Ehrhardt J, Yuh WTC (1993) Voxel processing techniques for antemortem study of neuroanatomy and neuropathology using magnetic resonance imaging. J Neuropsychiatry Clin Neurosci 5: 121–130

    PubMed  CAS  Google Scholar 

  6. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM (1997) Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacol Berl 131: 174–179

    Article  CAS  Google Scholar 

  7. Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H (1971) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System) Pharmakopsychiat 4: 201–211

    Article  Google Scholar 

  8. Baddeley A (1992) Working memory. Science 255: 556–559

    Article  PubMed  CAS  Google Scholar 

  9. Barta PE, Pearlson GD, Powers RE, Richards SS, Tune LE (1990) Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry 147: 1457–1462

    PubMed  CAS  Google Scholar 

  10. Barta E, Powers RE, Aylward EH, Chase GA, Harrie GJ, Rabins PV, Tune LE, Pearlson GD (1997) Quantitative MRI volume changes in late onset schizophrenia and Alzheimer’s disease compared to normal controls. Psychiatry Res 68: 65–75

    Article  PubMed  CAS  Google Scholar 

  11. Bäuml J, Kissling W, Pitschel-Walz G (1996) Psychoedukative Gruppen für schizophrene Patienten: Einfluss auf Wissensstand und Compliance, Ergebnisse der Münchner PIP-Studie. Nervenheilkunde 15: 145–150

    Google Scholar 

  12. Berzewski H, Helmchen H, Hippius H, Hoffmann H, Kanowski S (1969) Das klinische Wirkungsspectrum eines neuen Dibenzodiazepin-Derivates. W 108/HF 1854; 8-Chlor-11-(4’methyl)-piperazino-5-dibenzo[b,e] [1,4-]diazepin. Arzneim Forsch (Drug Res) 19: 495–496

    Google Scholar 

  13. Bigelow LB, Nashrallah HA, Rausher FP (1983) Corpus callosum thickness in chronic schizophrenia. Br J Psychiatry 142: 284–287

    Article  PubMed  CAS  Google Scholar 

  14. Bilder RM, Bogerts B, Ashtari M, Wu H, Alvir JM, Jody D, Reiter G, Bell L, Lieberman JA (1995) Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res 17: 47–58

    Article  PubMed  CAS  Google Scholar 

  15. Blackwood DHR, Whalley LJ, Christie JE, Blackburn IM, StClair DM, Mclnnes A (1987) Changes in auditory P3 event-related potential in schizophrenia and depression. Br J Psychiatry 150: 154–160

    Article  PubMed  CAS  Google Scholar 

  16. Bogerts B (1993) Recent advances in neuropathology of schizophrenia. Schizophr Bull 19 (2): 431–445

    Article  PubMed  CAS  Google Scholar 

  17. Bogerts B, Meertz E, Schonfeld-Bausch R (1985) Basal ganglia and limbic system pathology in schizophrenia. Arch Gen Psychiatry 43: 36–42

    Google Scholar 

  18. Bottlender R, Wegner U, Wittmann J, Strauss A, Möller H-J (1999) Deficit syndromes in schizophrenic patients 15 years after their first hospitalization: Preliminary results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 249 (suppl 4): IV/27-IV/36

    Google Scholar 

  19. Bottlender R, Jäger M, Groll C, Strauss A, Möller H-J (2001) Deficit states in schizophrenia and their association with the length of illness and gender. Psychiatry Clin Neurosci 251: 272–278

    Article  CAS  Google Scholar 

  20. Bottlender R, Strauss A, Möller H-J (2000) Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. Schizophrenia Res 44: 145–150

    Article  CAS  Google Scholar 

  21. Bottlender R, Sato T, Jäger M, Groll C, Strauss A, Möller HJ (2002) The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. Eur Arch Psychiatry Clin Neurosci 252: 226–231

    Article  PubMed  Google Scholar 

  22. Braus DF, Ende G, Weber-Fahr W, Sartorius A, Krier A, Hubrich-Ungureanu P, Ruf M, Stuck S, Henn FA (1999) Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients. Schizophrenia Res 39: 19–29

    Article  CAS  Google Scholar 

  23. Brücke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S (1992) Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 339: 497

    Article  PubMed  Google Scholar 

  24. Buchkremer G, Klingberg S, Holle R, Schulze Mönking H, Hornung WP (1997) Psychoeducational psychotherapy für schizophrenic patients and their key relatives or care-givers: results of a 2-year follow-up. Acta Psychiatr Scand 96: 483–491

    Article  PubMed  CAS  Google Scholar 

  25. Buckley PF, Friedman L, Wu D, Lai S, Meltzer HY, Haacke EM, Miller D, Lewin JS (1997) Functional magnetic resonance imaging in schizophrenia: initial methodology and evaluation of the motor cortex. Psych Res 74: 13–23

    Article  CAS  Google Scholar 

  26. Carpenter Jr WT, Heinrichs DW, Wagman AM (1988) Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 145: 578–583

    PubMed  Google Scholar 

  27. Chen CH, Liu MY, Wie FC, Koong FJ, Hwu HG, Hsiao KJ (1997) Further evidence of no association between Ser9Gly polymorphism of dopamine D3 receptor gene and schizophrenia. Am J Med Genet 74: 40–43

    Article  PubMed  CAS  Google Scholar 

  28. Chua SE, McKenna PJ (1995) Schizophrenia — a brain disease? A critical review of structural and functional cerebral abnormality in the disorder. Br J Psychiatry 166: 563–582

    Article  PubMed  CAS  Google Scholar 

  29. Dauphinais D, DeLisi LE, Crow TJ, Alexandropoulos K, Colter N, Tuma I, Gershon ES (1990) Reduction in temporal lobe size in siblings with schizophrenia: a magnetic resonance imaging study. Psychiatry Res Neuroimaging 35: 137–147

    Article  CAS  Google Scholar 

  30. DeLisi LE, Tew W, Xie A, Hoff AL, Sakuma M, Kushner M, Lee G, Shedlack K, Smith AM, Grimson R (1995) A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol Psych 38: 349–360

    Article  CAS  Google Scholar 

  31. Dresel S, Mager T, Rossmüller B, Meisenzahl E, Hahn K, Möller HJ, Tatsch K (1999) In vivo effects of olanzapine on striatal dopamine D2/D3 receptor binding in schizophrenic patients: an Iodine-123-Iodobenzamide single-photon emission tomography study. Eur J Nuc Med 26: 862–868

    Article  CAS  Google Scholar 

  32. Elliott R, Sahakian BJ (1995) The neuropsychology of schizophrenia: relations with clinical an neurobiological dimensions. Psychological Medicine 25: 581–594

    Article  PubMed  CAS  Google Scholar 

  33. Falkai B, Bogerts B, Schneider T, Greve B, Pfeiffer U, Pilz K, Gonsiorzcyk C, Majtenyi C, Ovary I (1995) Disturbed planum temporale asymmetry in schizophrenia. A quantitative post mortem study. Schizophr Res 14: 161–175

    Google Scholar 

  34. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49: 538–544

    Article  PubMed  CAS  Google Scholar 

  35. Flechsig P (1920) Anatomie des menschlichen Gehirns und Rückenmarks auf myelogenetischer Grundlage. Thieme, Leipzig

    Google Scholar 

  36. Ford JM, White PM, Csernansky JG, Faustman WO, Roth WT, Pfefferbaum A (1994) ERPs in schizophrenia: effects of antipsychotic medication. Biol Psychiatry 36: 153–170

    Article  PubMed  CAS  Google Scholar 

  37. Frodl-Bauch T, Gallinat J, Meisenzahl EM, Möller H-J, Hegerl U (1999) Subcomponents of the auditory P300 reflect different aspects of psychopathology in schizophrenia. Biol Psychiatry 45: 116–126

    Article  PubMed  CAS  Google Scholar 

  38. Gottesman II, Shields J (1982) Schizophrenia. The epigenetic puzzle. Cambridge University Press, Cambridge

    Google Scholar 

  39. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC (1998) A follow-up magnetic resonance imaging study of schizophrenia. Arch Gen Psych 55: 145–152

    Article  CAS  Google Scholar 

  40. Hegerl U, Juckel G, Müller-Schubert A, Pietzacker A, Gaebel W (1995) Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia? Acta Psychiatr Scand 91: 120–155

    Article  PubMed  CAS  Google Scholar 

  41. Hippius H, Stille G (1973) Zur künftigen Entwicklung der Neuroleptika. In: de 1a Fuente R, Weisman MN (eds) Psychiatry. Proceedings of the V. World Congress of Psychiatry, Mexico, DF, 25.11–4.12.1971, part 1, symposium 8. Elsevier, New York, pp 571–575

    Google Scholar 

  42. Juckel G, Muller-Schubert A, Gaebel W, Hegerl U (1996) Residual symptoms in schizoprenic outpatients. Psychiatry Res 65: 23–32

    Article  PubMed  CAS  Google Scholar 

  43. Juckel G, Muller-Schubert A, Gaebel W, Hegerl U (1996) Residual symptoms in schizoprenic outpatients. Psychiatry Res 65: 23–32

    Article  PubMed  CAS  Google Scholar 

  44. Kapur S, Zipurski RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155: 921–928

    Google Scholar 

  45. Kasper S, Tauscher J, Küfferle B, Hesselmann B, Barnas C, Brücke T (1998) IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics. Eur Psychiatry 13 (suppl 1): 9s–14s

    Article  CAS  Google Scholar 

  46. Kathmann N (1995) Psychologische und biologische Determinanten langsamer Augenfolge-bewegungen. In: Pawlik K (Hrsg) Bericht über den 39. Kongress der Deutschen Gesellschaft für Psychologie in Hamburg 1994, Schwerpunkt Persönlichkeit und Verhalten. Hogrefe, Göttingen, Bern, Toronto, S 328–334

    Google Scholar 

  47. Kathmann N, Wagner M, Rendtorff N, Schöchlin C, Engel RR (1995) Information processing during eye tracking as revealed by event-related potentials in schizophrenics, alcoholics, and healthy controls. Schizophrenia Research 16: 145–156

    Article  PubMed  CAS  Google Scholar 

  48. Kathmann N, Wagner M, Rendtorff N, Engel RR (1995) Delayed peak latency of the mismatch negativity in schizophrenics and alcoholics. Biol Psychiatry 37: 754–757

    Article  PubMed  CAS  Google Scholar 

  49. Keepers GA, Casey DE (1991) Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 148: 85–89

    PubMed  CAS  Google Scholar 

  50. Kendler KS (1983) Overview: a current perspective on twin studies of schizophrenia. Am J Psychiat 140: 1413–1425

    PubMed  CAS  Google Scholar 

  51. King DJ, Wilson A, Cooper (1991) The clinical correlates of neurological soft signs in chronic schizophrenia. Acta Psychiatr Scand 50: 425–462

    Google Scholar 

  52. Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ (1996) 123I IBZM SPECT for Imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 153: 183–190

    Google Scholar 

  53. Kornhuber J, Weller M (1994) Current status of biochemical hypothesis in the pathogenesis of schizophrenia. Nervenarzt 65: 741–754

    PubMed  CAS  Google Scholar 

  54. Lewis S (1996) Structural brain imaging in biological psychiatry. Br Med Bulletin 52: 465–473

    Article  CAS  Google Scholar 

  55. Lundstrom K, Turpin MP (1996) Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Com 225: 1068–1072

    Article  PubMed  CAS  Google Scholar 

  56. Mager T, Weilke FA, Leinsinger G, Dudel C, Heiss D, Günther W, Ulbricht D, Hahn K, Möller HJ (1996) Activation of the motor cortex in schizophrenics investigated by functional MR Imaging. Neuroimage 3: 497

    Article  Google Scholar 

  57. McCarley RW, Shenton ME, O’Donnell BF, Faux SF, Kikinis R, Nestor PG, Jolesz FA (1993) Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia. Arch Gen Psych 50: 190–197

    Article  CAS  Google Scholar 

  58. Meisenzahl EM, Kotter G, Marcuse A, Müller D, Leinsinger G, Heiss D, Möller HJ, Hegerl U (1998) The use of quantitative MRI and auditory evoked potentials in schizophrenic patients. Eur Arch Psych Clin Neurosci 248: 134

    Google Scholar 

  59. Meisenzahl EM, Leinsinger GL, Heiss DT, Mager T, Möller HJ (1998) Welche Erkenntnisse bringt die funktionelle MRT-Diagnostik hinsichtlich der Ätiopathogenese der Schizophrenie? In: Möller HJ, Müller N (Hrsg) Schizophrenie — Moderne Konzepte zur Diagnostik, Pathogenese und Therapie. Springer, Berlin, Heidelberg, S 185–194

    Google Scholar 

  60. Meisenzahl EM, Frodl T, Greiner J, Leinsinger G, Maag KP, Heiss D, Hahn K, Möller HJ (1999) Corpus callosum size in schizophrenia — a magnetic resonance imaging analysis. Eur Arch Clin Neurosci 249: 305–312

    Article  CAS  Google Scholar 

  61. Meisenzahl EM, N Kathmann, Zetzsche T, Heiss D, Leinsinger G, Möller HJ (1999) Localizing brain regions active in spatial and nonspatial working memory using fMRI. Pharmacopsychiatry 32: 196

    Google Scholar 

  62. Meisenzahl EM, Frodl T, Zetzsche T, Leinsinger G, Heiss D, Maag K, Hegerl U, Hahn K, Möller HJ (2000) Adhesio interthalamica in male patients with schizophrenia. Am J Psychiatry 157: 823–825

    Article  PubMed  CAS  Google Scholar 

  63. Meisenzahl EM, Frodl T, Zetzsche T, Leinsinger G, Maag K, Hegerl U, Hahn K, Möller HJ (2002) Investigation of a possible dienzephalic pathology in schizophrenia. Psychiatr Res Neuroimaging 115: 127–135

    Article  Google Scholar 

  64. Meisenzahl E, Dresel S, Schmitt G, Frodl T, Preuss U, Tatsch K, Hahn K, HJ Möller (2000) D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-Iodobenzamide SPECT Study. Psychopharmacology 14: 364–370

    Article  CAS  Google Scholar 

  65. Möller HJ (1993) Vorhersage des Therapieerfolges schizophrener Patienten. In: Möller HJ (Hrsg) Therapieresistenz unter Neuroleptikabehandlung. Springer, Wien, New York, S 1–12

    Google Scholar 

  66. Möller HJ (1995) The psychopathology of schizophrenia: an integrated view on positive symptoms. Int Clin Psychopharmacol 10 (suppl 3): 57–64

    Article  PubMed  Google Scholar 

  67. Möller HJ, Kissling W, von Zerssen D (1985) Vorhersage des Therapieerfolges unter neuroleptischer Akutbehandlung: Ergebnisse einer empirischen Untersuchung an 243 stationär behandelten schizophrenen Patienten. Fortschr Neurol Psychiatr 53: 370–383

    Google Scholar 

  68. Möller HJ, Bottlender R, Wegner U, Wittmann J, Strauß A (2000): Long-term course of schizophrenic, affective and schizoaffective psychosis: Focus on negative symptoms and their impact on glocal indicators of outcome. Acta Psychiatr Scand 102 (suppl 407): 54–57

    Article  Google Scholar 

  69. Möller HJ, Bottlender R, Groß A, Hoff P, Wittmann J, Wegner U, Strauß A (2002) The Kraepelinian dichotomy: Preliminary results of a 15-year follow-up study on functional psychoses: Focus on negative symptoms. Schizophr Res 56: 87–94

    Google Scholar 

  70. Müller N, Frenzel KH, Schwarz M, Wurl D, Hampel H, Penning R, Ackenheil M (1994) Expression of human heat-shock protein 70 antigens and gamma/delta T-cell receptor antigens in human central nervous tissue. Ann New York Acad Sci 741: 305–315

    Article  Google Scholar 

  71. Müller N, Dobmeier P, Empl M, Riedel M, Schwarz M, Ackenheil M (1997) Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur Psychiatry 12: 294–299

    Article  PubMed  Google Scholar 

  72. Müller N, Empl M, Riedel M, Schwarz MJ, Ackenheil M (1997) Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247: 308–313

    Article  PubMed  Google Scholar 

  73. Müller N, Schlesinger BC, Hadjamu M, Riedel M, Schwarz M, Ackenheil M, Wank R, Gruber R (1998) Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+g/d+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011. Schizophr Res 32: 69–71

    Article  PubMed  Google Scholar 

  74. Müller N, Riedel M, Ackenheil M, Schwarz MJ (1999) The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249 (suppl 4): IV/62-IV/68

    Google Scholar 

  75. Müller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R (1999) Increase in expression of adhesion molecule receptors on T-helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 156: 634–636

    PubMed  Google Scholar 

  76. Müller-Spahn F, Ackenheil M, Albus M, Naber D, Hippius H (1983) Biochemical and neuroendocrinological effects of chronic neuroleptic treatment. In: Pichot P, Berner P, Thaw K (eds) Psychiatry. The state of the art, vol. 3: Pharmacopsychiatry. Plenum Press, New York, pp 755–781

    Google Scholar 

  77. Müller-Spahn F, Ackenheil M, Bondy B, May G, Rüther E (1986) Growth hormone response to graded doses of apomorphine HCL in normals and schizophrenic patients: relation to psychotic decompensation. In: Shagass C et al (eds) Biological Psychiatry 1985. Elsevier, New York, pp 1074–1076

    Google Scholar 

  78. Müller-Spahn F, Ackenheil M, Albus M, Kurtz (1987) Neuroendokrinologische Untersuchungen bei schizophrenen Patienten nach Stimulation mit unterschiedlichen Dosierungen von Apomorphin. In: Beckmann H, Laux G (Hrsg) Biologische Psychiatrie. Springer, Berlin, Heidelberg, New York, S 117–121

    Google Scholar 

  79. Murray RM, O’Callaghan E, Castle DJ (1992) A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 18: 319–332

    Article  PubMed  CAS  Google Scholar 

  80. Naber D, Fischer H, Ackenheil M (1979) Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance? Communic Psychopharmacol 3: 59–65

    CAS  Google Scholar 

  81. Naber D, Finkbeiner C, Fischer B, Zander K-J, Ackenheil M (1980) Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms. Neuropsychobiology 6: 181–189

    Article  PubMed  CAS  Google Scholar 

  82. Naber D, Ackenheil M, Laakman G, Fischer H, von Werder K (1980) Basal and stimulated levels of prolactin, TSH and LH in serum of chronic schizophrenic patients long-term treated with neuroleptics. Pharmakopsychiatr Neuropsychopharmakol 13: 325–330

    Google Scholar 

  83. Naber D, Albus M, Müller F, Bürke H, Welter D, Ackenheil M, Hippius H (1982) β-endorphin, Cortisol and prolactin in serum of schizophrenic patients during long-term neuroleptic treatment and after withdrawal: relationships to psychopathology. Psychopharmacology bulletin 18: 224–226

    Google Scholar 

  84. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48: 648–654

    Article  PubMed  CAS  Google Scholar 

  85. Nuechterlein KH (1991) Vigilance in schizophrenia and related disorders. In: Steinhauer SR, Gruzelier JH, Zubin J (eds) Handbook of Schizophrenia. V. Neuropsychology, Psychophysiology and Information Processing. Elsevier, Amsterdam, pp 397–433

    Google Scholar 

  86. Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PJ, Nohria V, Kerwin RW (1996) Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a 123I IBZM single photon emission tomography ( SPECT) study. Psychopharmacol 124: 148–153

    Google Scholar 

  87. Riesenman C (1995) Antidepressant Drug Interactions and the Cytochrome P450 System, A Critical Appraisal. Pharmacotherapy 15 (suppl) 84S-99S

    PubMed  CAS  Google Scholar 

  88. Rietschel M, Naber D, Fimmers R, Möller H-J, Propping P, Nothen MM (1997) Efficacy and side effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 8: 1999–2003

    Article  PubMed  CAS  Google Scholar 

  89. Rosenthal R, Bigelow LB (1972) Quantitative brain measurements in chronic schizophrenia. Br J Psychiatry 121: 259–264

    Article  PubMed  CAS  Google Scholar 

  90. Rüther E (1986) Wirkungsverlauf der neuroleptischen Therapie. Verlaufsuntersuchungen bei der antipsychotischen Therapie mit Haloperidol und Clozapin. Gustav Fischer Verlag, Stuttgart, New York

    Google Scholar 

  91. Schäfer M, Rujescu D, Guntermann A, Giegling I, Dittert S, Möller H-J, Bondy B (1999) Response to haloperidol treatment and dopamine DRD2 receptor gene polymorphism. Current Opinion in Psychiatry, vol 12, suppl 2, July 1999, S59: FC-42–7

    Google Scholar 

  92. Schäfer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Möller H-J (2001) Association of short-term response to haloperidol treatment is associated with a polymorphism in the dopamine D (2) receptor gene. Am J Psychiatry 1158: 802–804

    Article  Google Scholar 

  93. Schaub A (1997) Bewältigungsorientierte Gruppentherapie bei schizophren und schizoaffektiv Erkrankten und ihren Angehörigen. In: Trenckmann U, Lasar M (Hrsg) Psycho-thera-peutische Strategien der Schizophreniebehandlung. Pabst, Berlin, S 95–120

    Google Scholar 

  94. Schaub A (1998) Cognitive-behavioural coping-orientated therapy: A new treatment model for clinical service and research. In: Perris C, McGorry P (eds) Cognitive psychotherapy of psychotic and personality disorders. Handbook of theory and practice. Wiley & Sons, Chichester, pp 91–109

    Google Scholar 

  95. Schaub A, Behrendt B, Brenner HD, Mueser KT, Liberman RP (1998) Training schizophrenic patients to manage their symptoms: Predictors of treatment response to the German version of the Symptom Management Module. Schiz Res 31: 121–130

    Google Scholar 

  96. Schaub A, Luderer HJ, Sibum B, Hornung P, Pitschel-Walz G, Bäuml J (1999) Psychoeducation: An important intervention in schizophrenia. Current Opinion in Psychiatry 12 (suppl 1): 440

    Google Scholar 

  97. Schaub A, Wolf B, Gartenmaier A, Froschmayr S (1999) Coping-orientated therapy in schizophrenia: Implementation and first results. XI World Congress of Psychiatry, Hamburg, p 169

    Google Scholar 

  98. Schaub A, Wolf B, Gartenmaier A, Kaiser A, Müller N, Möller H-J (2000) Bewältigungsorientierte Therapie und atypische Neuroleptika in einem integrierten Behandlungskonzept für Patienten mit schizophrenen Störungen. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde ( DGPPN ), Aachen

    Google Scholar 

  99. Schaub A, Wolf B, Charypar M, Möller H-J (2000) Neuropsychologische Defizite und Negativsymptomatik bei erstmals stationär behandelten Patienten mit schizophrenen Störungen. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde ( DGPPN ), Aachen

    Google Scholar 

  100. Schaub A (2002) Illness self-management programs in schizophrenia and severe affective disorders. In: Schaub A (ed) New family interventions and associated research in psychiatric disorders. Springer, Wien, New York, pp 229–247

    Chapter  Google Scholar 

  101. Schreiber H, Stolz-Born G, Kornhuber HH, Born J (1996) Elektrophysiologische Korrelate selektiver Aufmerksamkeit bei Kindern und Jugendlichen mit erhöhtem Schizophrenie-Risiko. Z Kinder Jugendpsychiatr Psychother 24: 282–292

    PubMed  CAS  Google Scholar 

  102. Schröder J, Wenz F, Schad LR, Baudeldistel K, Knopp MV (1995) Sensomotor cortex and supplementary motor area changes in schizophrenia. Br J Psychiatry 167: 197–201

    Article  PubMed  Google Scholar 

  103. Schwab SG, Albus M, Hallmayer J, Hönig S, Borrmann M, Lichtermann D, Ebstein RP, Ackenheil M, Lerer B, Risch N et al. (1995) Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. Nat Genet 11: 325–327

    Article  PubMed  CAS  Google Scholar 

  104. Schwab SG, Lerer M, Albus M, Maier W, Hallmayer J, Fimmers R, Lichtermann D, Minges J, Bondy B, Ackenheil M et al (1995) Potential linkage for schizophrenia on chromosome 22q12– q13: a replication study. Am J Med Genet 60: 436–443

    Article  PubMed  CAS  Google Scholar 

  105. Schwarz MJ, Ackenheil M, Riedel M, Müller N (1998) Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 253: 201–203

    Article  PubMed  CAS  Google Scholar 

  106. Schwarz MJ, Riedel M, Gruber R, Müller N, Ackenheil M (1998) Autoantibodies against 60-kD heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 248: 282–288

    Article  PubMed  CAS  Google Scholar 

  107. Schwarz MJ, Riedel M, Gruber R, Ackenheil M, Müller N (1999) Antibodies to Heat Shock Proteins in Schizophrenic Patients: Implications for the Mechanism of the Disease. Am J Psychiatry 156: 1103–1104

    Google Scholar 

  108. Schwarz MJ, Riedel M, Ackenheil M, Müller N (2000) Decreased Levels of Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in Unmedicated and Medicated Schizophrenic Patients. Biol Psychiat 47: 29–33

    Article  PubMed  CAS  Google Scholar 

  109. Shenton M, Kikinis R, Jolesz F, Pollak S, LeMay M, Wible C, Hokama H, Martin J, Metcalf D, Coleman M, McCarley R (1992) Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med 327: 604–612

    Google Scholar 

  110. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B (1998) Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 18: 45–48

    Article  PubMed  CAS  Google Scholar 

  111. Snyder PJ, Bogerts B,Wu H, Bilder R, Deoras K, Lieberman JA (1998) Absence of the adhesio interthalamica as a marker of early neurodevelopmental neuropathology in schizophrenia: an MRI and postmortem histological study. Journal of Neuroimaging 8: 159–163

    CAS  Google Scholar 

  112. Sperry R (1982) Some effects of disconnecting the cerebral hemispheres. Science 217: 1223–1226

    Article  PubMed  CAS  Google Scholar 

  113. Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmakopsychiat 4: 182–191

    Article  CAS  Google Scholar 

  114. Straub RE, MacLean CJ, O’Neil FA, Burke J, Murphy B, Duke F et al. (1995) A potential vulnerability locus for schizophrenia on chromosome 6p24–22: evidence for genetic heterogeneity. Nature Genet 11: 287–193

    Article  PubMed  CAS  Google Scholar 

  115. Strik WK, Dierks T, Franzek E, Maurer K, Beckmann H (1993) Differences in P300 amplitudes and topography between cycloid psychosis and schizophrenia in Leonhard’s classification. Acta Psychiatr Scand 87: 179–183

    Article  PubMed  CAS  Google Scholar 

  116. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR (1990) Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. New Engl J Med 322: 789–794

    Article  PubMed  CAS  Google Scholar 

  117. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, Hayashi K (1997) Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 7: 415–418

    Article  PubMed  CAS  Google Scholar 

  118. Tandon R, Greden JF (1991) Negative symptoms of schizophrenia: The need of conceptual clarity. Biol Psychiatry 30: 321–325

    Google Scholar 

  119. Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brücke T, Kasper S (1999) In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) 141: 175–181

    Article  CAS  Google Scholar 

  120. Tibbo P, Nopoulos P, Arndt S, Andreasen NC (1998) Corpus callosum shape and size in male patients with schizophrenia. Biol Psychiatry 44: 405–412

    Article  PubMed  CAS  Google Scholar 

  121. Tienari P, Sorri A, Lahti I, Naarala M, Wahlberg KE, Pohjola J, Moring J (1985) Interaction of genetic and psychosocial factors in schizophrenia. Acta Psychiat Scand (suppl 319 ) 71: 19–30

    Article  CAS  Google Scholar 

  122. Wildenauer D, Schwab SG, Eckstein GN, Zill P, Hoenig S, Hallmayer J, Albus M, Borrmann M, Ebstein RE, Lichtermann D, Lerer B, Risch RN, Maier W (1995) Searching for susceptibility genes in schizophrenia by affected sib pair analysis: evidence for loci in 22q, 5q and 6p. Am J Hum Genet 57 (suppl): 176

    Google Scholar 

  123. Wildenauer DB, Hallmayer J, Schwab SG, Albus M, Eckstein GN, Zill P, Honig S, Strauss M, Borrmann M, Lichtermann D, Ebstein RP, Lerer B, Risch N, Maier W (1996): Searching for susceptibility genes in schizophrenia by genetic linkage analysis. Cold Spring Harb Symp Quant Biol 61: 845–850

    Article  PubMed  CAS  Google Scholar 

  124. Wildenauer D, Schwab SG, Eckstein GN, Zill P, Hruschka K, Meier MA, Strauß M, Ackenheil M, Borrmann M, Albus M, Hallmayer J, Lichtermann D, Minges D, Ebstein RE, Lerer B, Maier W (1996) Gegenwärtiger Stand der Kopplungsuntersuchungen bei Schizophrenie. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg) Aktuelle Perspektiven der biologischen Psychiatrie. Springer, Berlin, Heidelberg

    Google Scholar 

  125. Witelson SF, Kigar DL (1988) Asymmetry in brain function follows asymmetry in anatomical form: gross microscopic, post-mortem and imaging studies. In: Boller F, Grafman J (eds) Handbook of Neuropsychology, vol 1. Elsevier, Amsterdam, pp 111–141

    Google Scholar 

  126. Zill P (1998) Mutations-, Haplotypen- und Expressionsanalyse des Morbus-Wilson-Gens, sowie Untersuchungen zur Assoziation und Kopplung psychiatrischer Erkrankungen. Dissertation, Ludwig-Maximilians-Universität, München

    Google Scholar 

  127. Zill P, Schäfer M, Riedel M, Rujescu D, Giegling I, Guntermann A, Bondy B (2000) A G-protein-b3-gene variant and response to haloperidol treatment. Am J Med Genet 96: 541

    Google Scholar 

Download references

Authors
  1. H.-J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität München, Nußbaumstr. 7, 80336, München, Deutschland

    Hanns Hippius (em. o. Professor für Psychiatrie) (em. o. Professor für Psychiatrie)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Möller, HJ. (2003). Aktuelle Schwerpunkte der Schizophrenieforschung. In: Hippius, H. (eds) Universitätskolloquien zur Schizophrenie. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57417-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57417-7_2

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63263-1

  • Online ISBN: 978-3-642-57417-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation